Recently, Sinopharm (stock code: 688136) introduced its product - Infliximab for Injection (class stop) ®） Successfully approved for listing in Indonesia. The Southeast Asian pharmaceutical market has always been one of Sinopharm's important advantage markets overseas. The approval of Inflixi in Indonesia further expands the sales area of the drug and provides new treatment options for local patients.

Quickly approved for listing, Inflixi's overseas progress refreshes

Infliximab for injection (class stop) ®）， Approved for marketing by the National Medical Products Administration in July 2021, it is the first domestically approved biosimilar drug of Infliximab, mainly used for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, adult ulcerative colitis, adult and children over 6 years old with Crohn's disease and fistula Crohn's disease.

In 2021 and 2022, Sinovac Pharmaceutical and Taizhou Mabotaike Pharmaceutical Co., Ltd. signed agreements to obtain biosimilars of Infliximab (class stop) ®） Commercial rights in over 30 countries and regions. As of now, it has obtained GMP certificates from Egypt and Brazil (PIC/S member countries), and has been approved for listing in Peru and Indonesia. It is expected that Infliximab will contribute significantly to Sinovac's overseas revenue by 2025, further consolidating the strength and scale of Sinovac's overseas platform.

It is reported that Sinopharm's own product, erythropoietin (EPO), was listed in Indonesia in 2005. The company has been working in the pharmaceutical market in Indonesia for nearly 20 years, maintaining a leading brand awareness and market share. Its cooperative clients include the top 5 pharmaceutical companies in Indonesia and the largest healthcare provider in Indonesia. After the approval of Infliximab in the Indonesian market, Sinopharm has accumulated three core products for local sales, namely human erythropoietin (EPO), human granulocyte colony-stimulating factor (GC), and Infliximab.

Deep cultivation, huge potential in the Indonesian pharmaceutical market

Sinopharm has been going global since 2000 and has achieved significant commercialization results in multiple emerging market countries, especially in Southeast Asia. Indonesia is the largest economy in ASEAN, and its pharmaceutical market also has a positive impact on the markets of other ASEAN countries. According to the official website of the Chinese Ministry of Foreign Affairs, Indonesia has a population of 281 million (as of October 2024), making it the fourth most populous country in the world. In 2023, Indonesia's gross domestic product was 20892.4 trillion Indonesian rupiah (approximately 1.37 trillion US dollars), a year-on-year increase of 5.05%. According to the annual GDP data released by the International Monetary Fund (IMF), Indonesia's 2023 GDP ranking ranks first in Southeast Asia and 16th in the world.

With the development of the Indonesian economy and the improvement of people's living standards, the demand for healthcare has also increased, and the demand for biosimilars and generic drugs in the pharmaceutical market has increased. According to the data released by the World Health Organization in 2023, the life expectancy in Indonesia is 71.3 years. The elderly population in Indonesia is also gradually increasing. According to the world's aging standards, a country or region with a population aged 65 and above of more than 7% is in an aging society. In 2023, the proportion of the population aged 65 and above in Indonesia will be 7.02%. The improvement of life expectancy and the trend of aging will make chronic disease treatment and management a major demand in the Indonesian pharmaceutical market.

In recent years, Sinopharm has been focusing on overseas commercialization. With its continued deep cultivation in emerging markets and in-depth layout in the EU market, it will continue to promote the globalization process of multiple products and provide high-quality drug treatment options for more patients.